Quantitative structure-pharmacokinetics relationships: I. Development of a whole-body physiologically based model to characterize changes in pharmacokinetics across a homologous series of barbiturates in the rat

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 25, Issue 3, 1997, Pages 277-312

  Blakey, Graham E ^a   Nestorov, Ivan A ^b,c   Arundel, Philip A ^a   Aarons, Leon J ^b   Rowland, Malcolm ^b  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Acad G Bonchev   (Bulgaria)

Author keywords

Barbiturates; Homologous series; Parameter optimization; Pharmacokinetics; Physiologically based model

Indexed keywords

5 ETHYL 5 HEPTYLBARBITURIC ACID; 5 ETHYL 5 METHYLBARBITURIC ACID; 5 ETHYL 5 NONYLBARBITURIC ACID; 5 ETHYL 5 OCTYLBARBITURIC ACID; 5 ETHYL 5 PENTYLBARBITURIC ACID; 5 ETHYL 5 PROPYLBARBITURIC ACID; BARBITAL; BARBITURIC ACID DERIVATIVE; BUTETHAL; HEXETHAL; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BOLUS INJECTION; BONE; BRAIN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTESTINE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; KIDNEY CLEARANCE; LIPOPHILICITY; LIVER; LIVER CLEARANCE; LUNG; MALE; MUSCLE; NONHUMAN; PANCREAS; PARAMETER; PERMEABILITY; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; SKIN; SPLEEN; STEADY STATE; STOMACH; TESTIS;

ADIPOSE TISSUE; ANIMALS; BARBITURATES; BLOOD VOLUME; BODY FLUID COMPARTMENTS; BRAIN; COMPUTER SIMULATION; DIGESTIVE SYSTEM; DRUG COMBINATIONS; INJECTIONS, INTRAVENOUS; LUNG; MALE; MODELS, BIOLOGICAL; MUSCULOSKELETAL SYSTEM; MYOCARDIUM; PERMEABILITY; RATS; RATS, SPRAGUE-DAWLEY; SKIN; STRUCTURE-ACTIVITY RELATIONSHIP; TESTIS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0031442434     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1025771608474     Document Type: Article

References (34)

1. A. Bernareggi and M. Rowland. Physiological modeling of cyclosporine kinetics in rat and man. J. Pharmacokin. Biopharm. 19:21-50 (1991).
2. S. Bjorkman, D. R. Stanski, H. Harashima, R. Dowrie, S. R. Harapat, D. R. Wada, and W. F. Ebling. Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model. J. Pharmacokin. Biopharm. 21:255-279 (1993).
3. S. Bjorkman, D. R. Wada, D. R. Stanski, and W. F. Ebling. Comparative pharmacokinetics of fentanyl and alfentanil in rats and humans based on parametric single-tissue models. J. Pharmacokin. Biopharm. 22:381-410 (1994).
4. R. Kawai, M. Lemaire, J.-L. Steimer, A. Bruelisauer, W. Niederberger, and M. Rowland. Physiologically based pharmacokinetic study on a cyclosporine derivative, SDZ IMM 125. J. Pharmacokin. Biopharm. 22:327-365 (1994).
5. L. E. Gerlovski and R. K. Jain. Physiologically based pharmacokinetic modeling: Principles and applications. J. Pharm. Sci. 72:1103-1129 (1983).
6. W. F. Ebling, D. R. Wada and D. R. Stanski. From piecewise to full pharmacokinetic modeling: Applied to thiopental disposition in the rat. J. Pharmacokin. Biopharm. 22:259-292 (1994).
7. S. Toon and M. Rowland. Structure-activity relationships among the barbiturates in the rat. J. Pharmacol. Exp. Ther. 225:752-763 (1983).
8. Y. Igari, Y. Sugiyama, S. Awazu, and M. Hanano. Comparative physiologically based pharmacokinetics of hexobarbital, phenobarbital and thiopental in the rat. J. Pharmacokin. Biopharm. 10:53-75 (1982).
9. N. Watari, Y. Sugiyama, N. Kaneniwa, and M. Hiura. Prediction of hepatic first-pass metabolism and plasma levels following intravenous and oral administration of barbiturates in the rabbit based on quantitative structure-pharmacokinetic relationships. J. Pharmacokin. Biopharm. 16:279-301 (1988).
10. K. Kakemi, T. Arita, R. Hori, and R. Konishi. Absorption and excretion of drugs XXXII. Absorption of barbituric acid derivatives from rat small intestine. Chem. Pharm. Bull. 15:1883-1887 (1967).
11. T. D. Yih and J. M. Van Rossum. Pharmacokinetics of some homologous series of barbiturates in the intact rat and in the isolated perfused rat liver. J. Pharmacol. Exp. Ther. 203:184-192 (1977).
12. J. M. Mayer, S. D. Hall, and M. Rowland. Relationship between lipophilicity and tubular reabsorption for a series of 5-alkyl-5-ethyl barbituric acids in the isolated perfused rat kidney preparation. J. Pharm. Sci. 77:359-364 (1988).
13. R. J. Prankerd and R. H. McKeown. Physicochemical properties of barbituric acid derivatives. 2: Partition coefficients of 5, 5-disubstitiuted barbituric acids at 25°C. Int. J. Pharm. 83:25-37 (1992).
14. R. Pinal and S. H. Yalkowsky. Solubility and partitioning VII: Solubility of barbiturates in water. J. Pharm. Sci. 76:75-85 (1987).
15. S. H. Steiner, M. J. Moor, and M. H. Bickel. Kinetics of distribution and adipose tissue storage as a function of lipophilicity and chemical structure. 1. Barbiturates. Drug Metab. Dispos. 19:8-14 (1991).
16. B. B. Brodie, E. Bernstein, and L. C. Mark. The role of body fat in limiting the duration of action of thiopental. J. Pharm. Pharmacol. 105:421-426 (1952).
17. K. B. Bischoff and R. L. Dedrick. Thiopental pharmacokinetics. J. Pharm. Sci. 57:1346-1351 (1968).
18. M. Rowland and T. N. Tozer. Clinical Pharmacokinetics: Concepts and Applications, 3rd ed., Lea and Febiger, Philadelphia, 1995.
19. J. M. Gallo, F. C. Lam, and D. G. Perrier. Area method for the estimation of partition coefficients for physiological pharmacokinetic models. J. Pharmacokin. Biopharm. 15:271-280 (1987).
20. D. Verotta, L. B. Steiner, W. F. Ebling, and D. Stanski. A semiparametric approach to physiological flow models. J. Pharmacokin. Biopharm. 17:463-491 (1989).
21. B. Davies and T. Morris. Physiological parameters in laboratory animals and humans. Pharm. Res. 10:1093-1095 (1993).
22. A. C. Heatherington. A physiological based pharmacokinetic model for drug distribution. Ph.D. Thesis, Faculty of Science, University of Manchester, 1994.
23. R. J. Lutz, R. L. Dedrick, and H. B. Matthews. A preliminary pharmacokinetic model for several biphenyls in the rat. Drug Metab. Dispos. 5:386-396 (1977).
24. H.-S. G. Chen, and J. F. Gross. Estimation of tissue to plasma partition coefficients used in physiological pharmacokinetic models. J. Pharmacokin. Biopharm. 7:117-125 (1979).
25. H. Remmer. Induction of drug metabolising enzyme systems in the liver. Eur. J. Clin. Pharmacol. 5:116-136 (1972).
26. K. C. Skolleborg, J. E. Gronbech, K. Grong, F. E. Abyholm, and J. Lekven. Distribution of cardiac output during pentobarbital versus midazolam/fentanyl/fluanisone anaesthesia in the rat. Lab. Animals 24:221-227 (1990).
27. M. Gumbleton, P. J. Nicholls, and G. Taylor. Differential influence of laboratory anaesthetic regimens upon renal and hepatosplanchnic haemodynamics in the rat. J. Pharm. Pharmacol. 42:693-697 (1990).
28. P. C. Kremser and B. L. Gewert. Effect of pentobarbital and haemorrhage on renal autoregulation. Am. J. Physiol. 249:F356-F360 (1985).
29. W. C. Seyde, L. McGowan, N. Lund, B. Duling, and D. E. Longnecker. Effects of anaesthetics on regional hemodynamics in normovolaemic and hemorrhaged rats. Am. J. Physiol. 249:H164-H173 (1985).
30. M. J. A. P. Daemen, H. H. W. Thijssen, and H. F. Vervoot-Peters. The effect of pentobarbitone anaesthesia and hypothermia on the hepatic clearance of indocyanine green and S(-)-acenocoumarol in the rat. J. Pharm. Pharmacol. 38:122-125 (1986).
31. Y. Higashi, N. Notoji, R. Yamajo, and N. Yata. Effect of anaesthesia on drug disposition in the rat. J. Pharmacobiodyn. 5:112-119 (1982).
32. H. B. Waynforth. Experimental and Surgical Techniques in the Rat, Academic Press, London, 1980, pp. 95-97.
33. C.-H. Chou, A. M. Evans, G. Fornasini, and M. Rowland. Relationship between lipophilicity and hepatic dispersion and distribution for a homologous series of barbiturates in the isolated perfused in situ rat liver. Drug Metab. Dispos. 21:933-938 (1993).
34. S. J. Hague, S. M. Nugent, and B. Ford. Computer-based documentation for the NAG library. Lecture Notes Comput. Sci. 142:91-127 (1982).